Technology to track individual genetic variation in clinical trials is being more widely used. The latest deal Illumina announced is a $7 million genotyping services agreement to support prostate cancer, with researchers funded by Cancer Research UK, a charity.Illumina’s service group will conduct whole-genome genotyping (greater than 550,000 single nucleotide polymorphisms, or SNPs, per sample) for 4,000 well-classified prostate patients and controls. A second phase of the project will involve development of a custom, 12-sample BeadChip that will enable analysis of 24,000 SNPs per sample on 8,000 samples. Both phases will use Illumina’s Sentrix BeadChips and Infinium assay. This is the second large-scale genotyping agreement signed between the two organizations in the last six months. Its structure follows a November 2005 agreement under which Illumina is genotyping colorectal cancer samples and controls for Cancer Research UK.